UNSPSC 51343815: Lamivudine/stavudine

This classification denotes a combination drug for treatment of HIV. The first component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The second component, STAVUDINE, has US FDA Unique Ingredient Identifier of BO9LE4QFZF.

UNSPSC 51343815 Lamivudine/stavudine is a Commodity code that does not reflect active state and local procurement activity in the recent opportunities provided. The code names a specific antiretroviral pharmaceutical combination used in HIV treatment, yet the recent opportunities tagged under this code are predominantly informational vendor events (trade shows, reverse trade shows, vendor forums, open houses, and networking sessions), pharmaceutical procurement unrelated to lamivudine/stavudine, and medical supply contracting for oxygen cylinders, naloxone, emergency medical services pharmaceuticals, and forensic drug standards. The one substantive pharmaceutical procurement in the dataset—Seminole County, Florida's purchase of naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023)—addresses opioid overdose reversal, not HIV antiretroviral therapy. The City of Tucson Fire Department's solicitation (260305ITQ, due June 24, 2026) covers BLS and ALS pharmaceuticals, vending machines, and inventory management systems for emergency medical response, again unaligned with the code's stated product.

No recent state or local government solicitations specifically request lamivudine/stavudine or comparable HIV antiretroviral pharmaceutical supply contracts. The code shows no documented purchasing activity by state health departments, county health systems, municipalities, school districts, or other typical state and local buyers. The mismatch between the code's narrow therapeutic scope and the broad vendor-outreach and medical supply notices in the opportunity block suggests either tagging error in the source data or absence of active demand for this specific drug class in the state and local procurement pipeline at present. Vendors should monitor state Medicaid procurement offices, county health and human services departments, and state pharmacy benefits programs for future solicitations in HIV pharmaceutical categories, but current signals under this code do not support active pursuit.